Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tipranavir

FDA-approved product (capsule, oral), marketed as Aptivus.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Tipranavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hemorrhage
  • HIV infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE09

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tipranavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tipranavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children

    NCT00076999 · start 2003-11

    Registered record
    Registry ID
    NCT00076999
    Conditions
    HIV Infections
    Interventions
    TPV oral solution; TPV oral solution; RTV oral solution; RTV oral solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-11
    Completion
    Not recorded
    Enrolment
    115

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTPV oral solution; TPV oral solution; RTV oral solution; RTV oral solution
    PhasePhase 1
    Registry statusCompleted

  • Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency

    NCT02249442 · start 2003-10-01

    Registered record
    Registry ID
    NCT02249442
    Conditions
    Hepatic Insufficiency
    Interventions
    Tipranavir (TPV); Ritonavir (r)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-10-01
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Insufficiency
    InterventionTipranavir (TPV); Ritonavir (r)
    PhasePhase 1
    Registry statusCompleted

  • Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male Subjects

    NCT02251158 · start 2003-10

    Registered record
    Registry ID
    NCT02251158
    Conditions
    Healthy
    Interventions
    Tipranavir oral solution; Tipranavir capsules; Ritonavir oral solution; Ritonavir soft gel capsules; High fat breakfast
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-10
    Completion
    Not recorded
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTipranavir oral solution; Tipranavir capsules; Ritonavir oral solution; Ritonavir soft gel capsules +1 more
    PhasePhase 1
    Registry statusCompleted

  • Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult Volunteers

    NCT02251171 · start 2003-08

    Registered record
    Registry ID
    NCT02251171
    Conditions
    Healthy
    Interventions
    Tipranavir; Ritonavir; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-08
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTipranavir; Ritonavir; Rifabutin
    PhasePhase 1
    Registry statusCompleted

  • Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir

    NCT02251769 · start 2003-08

    Registered record
    Registry ID
    NCT02251769
    Conditions
    Healthy
    Interventions
    Tipranavir; Ritonavir; Clarithromycin; High-Fat Test Meal
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-08
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTipranavir; Ritonavir; Clarithromycin; High-Fat Test Meal
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

    NCT00042289 · start 2003-06-09

    Registered record
    Registry ID
    NCT00042289
    Conditions
    HIV Infections
    Interventions
    atazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3; elvitegravir/cobicistat; dolutegravir; tenofovir alafenamide fumarate (TAF); TAF w/cobicistat; TAF w/cobicistat or ritonavir; efavirenz; darunavir/cobicistat; lopinavir/ritonavir dosage #1; atazanavir/ritonavir/tenofovir dosage #1; rifampicin; ethambutol; isoniazid; pyrazinamide; kanamycin; amikacin; capreomycin; moxifloxacin; levoflaxacin; ofloxacin; ethionamide/prothionamide; terizidone/cycloserine; para-aminosalicylic acid (PAS); high dose INH; bedaquiline; clofazamine; delamanid; linezolid; pretomanid; ethinyl estradiol; etonogestrel implant; nevirapine; amprenavir; abacavir; lopinavir/ritonavir dosage #2; indinavir/ritonavir dosage #1; fosamprenavir/ritonavir; lopinavir/ritonavir dosage #3; atazanavir/ritonavir dosage #1; didanosine delayed release (Videx® EC); emtricitabine; tenofovir; nelfinavir dosage #1; tipranavir/ritonavir; lopinavir/ritonavir dosage #4; ralteg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-06-09
    Completion
    2020-09-30
    Enrolment
    1,578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionatazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3 +45 more
    PhaseNot recorded
    Registry statusCompleted

  • Effects of Single-dose and Steady-state TPV/RTV on the Steady-state Pharmacokinetics of Fluconazole in Healthy Adult Volunteers

    NCT02195466 · start 2003-06

    Registered record
    Registry ID
    NCT02195466
    Conditions
    Healthy
    Interventions
    Tipranavir (TPV); Ritonavir (RTV); Fluconazole (FCZ)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-06
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTipranavir (TPV); Ritonavir (RTV); Fluconazole (FCZ)
    PhasePhase 1
    Registry statusCompleted

  • Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

    NCT00062660 · start 2003-05

    Registered record
    Registry ID
    NCT00062660
    Conditions
    HIV Infections
    Interventions
    Tipranavir
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    2003-05
    Completion
    2014-04
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTipranavir
    PhaseNot recorded
    Registry statusApproved for marketing

  • Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

    NCT00056641 · start 2003-02-18

    Registered record
    Registry ID
    NCT00056641
    Conditions
    HIV Infections
    Interventions
    tipranavir; ritonavir; saquinavir; amprenavir; lopinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-02-18
    Completion
    Not recorded
    Enrolment
    328

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventiontipranavir; ritonavir; saquinavir; amprenavir +1 more
    PhasePhase 2
    Registry statusCompleted

  • HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

    NCT00192660 · start 2003-02

    Registered record
    Registry ID
    NCT00192660
    Conditions
    HIV-Associated Lipodystrophy Syndrome; Cardiovascular Disease
    Interventions
    Lamivudine; Stavudine; Didanosine; Zidovudine; Tenofovir; Abacavir; Efavirenz (EFV); Nevirapine; Indinavir; Saquinavir; Amprenavir; Ritonavir; Nelfinavir; Tipranavir; enfuvirtide (T20)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-02
    Completion
    2007-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-Associated Lipodystrophy Syndrome; Cardiovascular Disease
    InterventionLamivudine; Stavudine; Didanosine; Zidovudine +11 more
    PhasePhase 4
    Registry statusCompleted

  • Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

    NCT00054717 · start 2003-01

    Registered record
    Registry ID
    NCT00054717
    Conditions
    HIV Infections
    Interventions
    Tipranavir; Ritonavir(r); Comparator Protease Inhibitor (CPI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-01
    Completion
    Not recorded
    Enrolment
    630

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTipranavir; Ritonavir(r); Comparator Protease Inhibitor (CPI)
    PhasePhase 3
    Registry statusCompleted

  • Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult Volunteers

    NCT02245438 · start 2002-05

    Registered record
    Registry ID
    NCT02245438
    Conditions
    Healthy
    Interventions
    Tipranavir low dose; Tipranavir high dose; Ritonavir low dose; Ritonavir high dose; Norethindrone-Ethinyl Estradiol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2002-05
    Completion
    Not recorded
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTipranavir low dose; Tipranavir high dose; Ritonavir low dose; Ritonavir high dose +1 more
    PhasePhase 1
    Registry statusTerminated

  • Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals

    NCT00034866 · start 2002-04

    Registered record
    Registry ID
    NCT00034866
    Conditions
    HIV Infections
    Interventions
    Protease inhibitor tipranavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-04
    Completion
    2002-10
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionProtease inhibitor tipranavir
    PhasePhase 2
    Registry statusCompleted

  • Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult Volunteers

    NCT02253823 · start 2001-12

    Registered record
    Registry ID
    NCT02253823
    Conditions
    Healthy
    Interventions
    EFV; TPV/RTV - low dose; TPV/RTV - high dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-12
    Completion
    Not recorded
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionEFV; TPV/RTV - low dose; TPV/RTV - high dose
    PhasePhase 1
    Registry statusCompleted

  • Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers

    NCT02249416 · start 2001-11

    Registered record
    Registry ID
    NCT02249416
    Conditions
    Healthy
    Interventions
    Tipranavir (TPV) low; Ritonavir (RTV) low; Tipranavir (TPV) high; Ritonavir (RTV) high; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-11
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTipranavir (TPV) low; Ritonavir (RTV) low; Tipranavir (TPV) high; Ritonavir (RTV) high +1 more
    PhasePhase 1
    Registry statusCompleted